Skip to main content
Sign In

Scott C N Oliver, MD

Associate Professor

Vitreoretinal Diseases and Surgery, Chief
Director, Eye Cancer Program
Associate Program Director, Vitreoretinal Diseases and Surgery Fellowship
Department of Ophthalmology
University of Colorado School of Medicine
UCHealth Eye Center - Anschutz Medical Campus
1675 Aurora Court, Mail Stop F-731
Aurora, CO  80045

Appointments:  (720) 848-2020

Curriculum Vitae

Dr. Oliver specializes in the management of retinal diseases and tumors of the eye, including expertise in macular degeneration, diabetic retinopathy, retinal vein and artery occlusion, retinal detachment, macular hole, macular pucker, retinopathy of prematurity, choroidal melanoma and retinoblastoma.  
Dr. Oliver is an investigator in national clinical trials and in basic science research.  His research interests include improving treatment for choroidal melanoma, macular degeneration, and diabetic eye disease.

Diabetic retinopathy, Retinal detachment, Age-related macular degeneration, Retinal vascular disease, Retinal vein occlusion, Proliferative vitreoretinopathy, Complications of cataract surgery, Macular hole, Epiretinal membrane, Retinopathy of prematurity, Choroidal melanoma, Retinoblastoma, Intraocular tumors.

Laser photocoagulation, Vitrectomy, Scleral buckling, Plaque brachytherapy.

Argus II Retinal Prosthesis System
Lampalizumab for Geographic Atrophy Secondary to AMD (SPECTRI)
Long-term Safety of Lampalizumab for Geographic Atrophy Secondary to AMD (OMASPECT)
Ranibizumab vs. Laser Therapy for Treatment of Infants Born Prematurely With ROP (RAINBOW)
Ranibizumab Port Delivery System for Patients with Subfoveal Neovascular AMD (LADDER)
Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma


  • AART - anecortave acetate for wet amd
  • Anti-PDGF Combination Injection for New Wet Macular Degeneration
  • BRAVO - ranibizumab for BRVO
  • CRUISE - ranibizumab for CRVO
  • Fenretinide for GA in AMD
  • HARBOR - high-dose ranibisumab for wet-AMD
  • HORIZON - ranibizumab extension study for wet-AMD and RVO
  • MIVI-TRUST 006 - microplasmin for VMT
  • Ocriplasmin for Injection for Wet Macular Degeneration and Vitreomacular Adhesion
  • ORION - ranibizumab for NAION
  • Posurdex DME
  • Posurdex RVO
  • RISE - ranibizumab for DME
  • Thrombogenics MIVI III - microplasmin before surgical vitrectomy


  • Medical School: University of Colorado School of Medicine
  • Residency: Ophthalmology, University of Colorado School of Medicine
  • Fellowship: Vitreoretinal Surgery and Disease, Jules Stein Eye Institute, UCLA
  • Fellowship: Ophthalmic Oncology, Jules Stein Eye Institute, University of California Los Angeles

   2016  Cure Ocular Melanoma (OM) Vision of Hope Award, Melanoma Research Foundation
   2014  Honor Award Recipient, American Society of Retina Specialists
   2011  Academic Faculty Teaching Award, Department of Ophthalmology, University of Colorado
   2011  Nomination, President’s Award for World Class Care, University of Colorado Hospital
   2008  Fellow’s Teaching Award, Jules Stein Eye Institute, UCLA
   2005-2006 Elected Chief Resident, Department of Ophthalmology, University of Colorado Denver
   2003  Intern of the Year, Exempla Saint Joseph Hospital, Denver, CO
   2002  Alpha Omega Alpha, University of Colorado
   1998  Phi Beta Kappa, Trinity University
   1994  Eagle Scout

Scott C N Oliver, MD